

# **Index**

- A $\beta$**  *See* amyloid  $\beta$  protein  
**ABri** 242, 243, 247  
**acetylcholine** 48  
 **$\alpha_1$ -ACT** *See*  $\alpha_1$ -antichymotrypsin  
**activated microglia** 57; 91; 217; 227; 288; 305; 328  
**activated protein C** 50; 57  
**acute brain injury** 81; 93; 94  
**acute phase proteins** 51; 207; 208; 209; 215  
**advanced glycation end products (AGEs)** 46; 325; 341  
**aged dogs** 26; 184; 313; 314; 315; 321; 322  
   **CAA** 313  
**AGEs** *See* advanced glycation end products  
**alcohol** 51  
**Alzheimer's disease**  
   **apolipoprotein E** 84  
   **autosomal dominant** 182  
   **blood-brain barrier** 24; 190; 193; 329  
   **CAA** 5; 9; 23; 157; 180; 208; 252; 268; 281; 295  
   **CAA-related hemorrhage** 87  
   **HCHWA-D** 103; 224  
   **leukoencephalopathy** 69  
   **pericytes** 268  
   **risk factors** 43  
   **smooth muscle cells** 251; 268  
   **transgenic mice** 295  
**amyloid**  
   **canine** 314  
   **PrP** 239; 241  
**amyloid  $\beta$  protein (A $\beta$ )**  
   **accumulation** 305  
   **aggregation** 332  
   **capillaries** 183  
   **cerebrovascular cells** 275  
   **chemical analysis** 158  
   **circulating** 169, 326  
   **clearance** 257, 327, 336  
   **cortical vessels** 159  
   **C-terminal** 168, 181, 317  
   **C-terminal** 180, 184, 227, 228  
   **cytotoxicity** 215; 270; 273; 274; 326; 328; 333; 364  
   **endosomes** 253  
   **end-specific antibodies** 297  
   **fibrillogenesis** 270; 326; 327; 335  
   **immunohistochemistry** 180  
   **interactions with ApoE** 86; 335  
   **interactions with ApoJ** 32; 33; 326; 327; 329  
   **internalization** 253; 255; 256  
   **isoforms** 179; 268; 297 *See also*  
     amyloid  $\beta_{1-40}$ , amyloid  $\beta_{1-42}$   
   **isolation** 158  
   **leptomeningeal vessels** 158  
   **lysosomes** 253  
   **neuronal source** 302  
   **neurotoxicity** 273  
   **N-terminal** 164; 168  
   **N-terminal heterogeneity** 184; 227; 228  
   **origin** 169; 193; 231; 258; 260; 302; 304; 327  
   **perivascular deposits** 210; 228  
   **plasma-derived** 327; 329  
   **post-translational modifications** 164  
   **receptors** 328  
   **sink** 301, 302  
   **toxicity** 275  
   **vasoactivity** 282, 283, 285, 286  
   **vasoconstriction** 282, 284  
**amyloid  $\beta$  protein binding**  
   **smooth muscle cells** 252  
**amyloid  $\beta$  precursor protein (APP)**  
   **familial syndromes** 138  
   **metabolism** 103, 112  
   **mutation** 104  
   **pericytes** 272  
   **smooth muscle cells** 272; 273  
**amyloid  $\beta$  precursor protein gene**  
   **Arctic mutation** 110  
   **Dutch mutation** 110; 111; 113; 114; 231  
   **Flemish mutation** 104; 107; 110; 111; 113; 231  
   **Florida mutation** 108; 110; 111; 118; 184; 187; 296; 297; 302  
   **Italian mutation** 108  
   **London mutation** 110; 112; 295  
   **Swedish mutation** 110; 111; 112; 182; 184; 297; 327; 335  
   **transgenics** *See* transgenic mice  
**amyloid  $\beta_{1-40}$**  26; 32; 33; 112; 227; 230; 252; 254; 256; 266; 269; 271; 273; 284; 287; 289; 297; 302; 326; 329; 332; 335

- amyloid  $\beta_{1-42}$  26; 112; 169; 227; 230; 252; 253; 258; 266; 268; 270; 274; 296; 297; 314; 317; 326; 332; 335
- amyloid  $\beta_{42}$  seeding 185; 303
- amyloid  $\beta$ -associated proteins 186; 207; 208; 210; 211; 213; 215; 227; 229; 327
- HCHWA-D 210
- senile plaques 210
- source 213; 214
- amyloid P component 125; 131; 191; 194; 209; 211; 218
- amyloidosis
- Finnish type 238
- aneurysms 67; 76; 88; 90; 93
- angiitis 17; 60; 137; 144; 147; 149; 150; 151; 153; 154; 155
- granulomatous 147; 150
- animal models 26; 61; 74; 92; 171; 282; 295; 296; 313; 315; 318; 327; 345 *See also* transgenic mouse models
- antibody cationization 29
- $\alpha_1$ -antichymotrypsin ( $\alpha_1$ -ACT) 85; 170; 207; 209; 218; 229; 315; 326; 327
- anti-inflammatory drugs 288
- anti-oxidants 275
- ApoE *See* apolipoprotein E
- ApoJ *See* apolipoprotein J; *See also* clusterin
- apolipoprotein E (ApoE) 26; 32; 33; 227; 230; 252; 254; 256; 266; 270; 272; 274; 281; 284; 287; 297; 302; 326; 332; 335
- allele frequencies 83; 88; 89
- CAA 84
- CAA-related hemorrhage 87
- deficient mice 93
- genetic linkage 84
- genotype 81; 83; 89; 170
- interactions with A $\beta$  86; 335
- internalization 253
- knockout mice 85; 101
- nonhuman primates 317
- apolipoprotein J (ApoJ) 26; 112; 169; 227; 230; 252; 258; 266; 268; 270; 272; 274; 296; 297; 314; 317; 326; 332; 335 *See also* clusterin
- apoptosis 33; 211; 325; 326; 327; 329; 330; 332
- APP *See* amyloid  $\beta$  precursor protein
- APP670/671 110; 111; 184; 297
- APP692 110; 111; 112
- APP693 110; 111; 112; 113; 184
- APP716 110
- APP717 100; 110; 111; 118; 184; 187; 296; 297; 302
- arachidonic acid 288; 291
- Arctic mutation *See* amyloid  $\beta$  precursor protein gene
- arterial dissection 63
- arteriolar fibrosis 150
- arteriolar rupture 146
- arteriosclerosis 65; 67
- aspirin 12
- atherosclerosis 61; 149; 150; 197; 254; 257
- atrial fibrillation 47
- BBB *See* blood-brain barrier
- bigenic mice
- APP and PS-1 335
- PDAPP and TGF $\beta$ 1 300
- Binswanger's disease (BSLE) 9; 17; 59; 66; 68; 76; 199; 243
- birefringence 25; 123; 124; 141; 145; 158
- bleeding 7; 186; 224
- subarachnoid 145
- blood-brain barrier (BBB) 21; 23; 37; 38; 39; 40; 41; 70; 73; 77; 78; 169; 175; 189; 190; 200; 201; 202; 203; 214; 216; 263; 314; 318; 324; 325
- function 194; 196
- permeability 24
- transport of ApoE 336
- transport of ApoJ 330
- transport of A $\beta$  33; 35; 327; 329
- Boston criteria 10; 12
- Braak & Braak 140
- BSLE *See* Binswanger's disease
- C reactive protein 194
- C1q 208; 211; 213; 215; 217; 229; 328
- See also* complement factors
- C5b-9 208; 211; 213; 215 *See also* complement factors
- CAA *See* cerebral amyloid angiopathy
- CAA-AMs *See* CAA-associated microangiopathies
- CAA-associated microangiopathies 67; 137; 143; 148; 149

- CAA-related hemorrhage 3; 4; 5; 6; 7;  
10; 11; 12; 22; 81; 86; 87; 88; 89; 90;  
92; 93; 111; 139; 144; 147  
Alzheimer's disease 87  
ApoE 87  
ApoE allele frequency 89  
ApoE genotype 87; 90  
Boston criteria 10; 12  
risk factors 4
- CADASIL 59; 60; 70; 71; 72; 73; 77  
calcification 62; 149; 228  
cardiovascular disease 47; 198  
Cardiovascular Health Study 47; 69; 77  
cathepsin D 315  
cationized antibody  
  intravenous administration of 30  
CERAD 18; 140; 152; 201; 261; 276;  
  281; 292  
cerebral amyloid angiopathy (CAA) *See*  
  *also* vascular amyloid  
   $\alpha_1$ -antichymotrypsin 315  
  acute phase proteins 209  
  AD-related 138  
  aged dogs 313  
  amyloid P 209  
  angiitis 151  
  animal models 26  
  ApoE 84; 85; 209; 315  
  APP23 transgenic mice 300  
  A $\beta$  158; 181; 184  
  A $\beta$  isoforms 158; 179  
  A $\beta$  species 158  
  A $\beta$ -associated proteins 209; 215  
  biopsy-proven 145  
  calcification 149  
  canine 314  
  cathepsin D 315  
  cerebral hemorrhage 138  
  chemical analysis 158  
  clinical manifestation 4  
  complement factors 209  
  cynomolgus monkeys 317  
  cystatin C 209; 315  
  diagnosis 11; 21  
  glycolipids 161  
  glycoproteins 161  
  grading 140; 141  
  HCHWA-D 184; 224  
  hemorrhage 197  
  hemorrhagic strokes 196  
  HSPGs 209  
  immunohistochemistry 179  
  inflammatory proteins 209  
  inflammatory reaction 151  
  ischemic lesions 138  
  mechanism of A $\beta$  deposition 185  
  mutations 5  
  neuroimaging 21  
  neurons 302  
  nonhuman primates 314; 316; 319  
  origin 169; 193; 231; 258; 260; 302;  
    304; 327  
  pericytes 255; 274  
  relation to senile plaques 139  
  rhesus monkeys 317  
  risk factors 5  
  severity 139; 142  
  smooth muscle cells 255; 274  
  sporadic 138  
  stroke 138  
  Tg2576 transgenic mice 297; 298;  
    299; 301  
  transgenic mice 296  
  treatment 12  
cerebral autosomal dominant arteriopathy  
  with subcortical infarcts and  
  leukoencephalopathy *See* CADASIL  
cerebral blood flow 23; 157; 171; 177;  
  282; 293  
cerebral hemorrhage 4; 5; 6; 12; 14; 15;  
  16; 18; 31; 65; 75; 82; 86; 88; 89; 92;  
  93; 94; 95; 97; 98; 99; 100; 101; 103;  
  104; 110; 114; 115; 116; 117; 118;  
  121; 122; 123; 129; 130; 131; 132;  
  133; 137; 138; 140; 141; 144; 145;  
  146; 147; 148; 153; 154; 155; 173;  
  182; 183; 187; 188; 196; 197; 204;  
  209; 218; 219; 220; 223; 231; 232;  
  233; 234; 235; 237; 238; 244; 245;  
  257; 265; 266; 276; 277; 279; 306;  
  307; 308; 310; 316; 321; 322; 323;  
  324; 327; 339; 340; 341; 344  
cerebrospinal fluid (CSF) 8; 11; 12; 18;  
  22; 28; 37; 39; 40; 86; 113; 118; 125;  
  132; 176; 179; 194; 203; 205; 232;  
  236; 256; 261; 263; 326; 337; 338  
cerebrovascular amyloidosis - British  
  type *See* familial British dementia  
cerebrovascular cells 265; 266; 275 *See*  
  *also* pericytes, smooth muscle cells

- A $\beta$  275
  - A $\beta$  toxicity 273
  - cerebrovascular disease 59
  - cerebrovascular lesions
    - distribution 191
  - chaperone 128; 129; 170; 176; 216; 335; 344
  - Charcot-Bouchard aneurysms 66; 74; 76; 141; 149
  - cholesterol 46
  - choroid plexus 175; 204; 330; 332; 333; 336; 342
  - Chrysamine G 26
  - circle of Willis 61; 62; 225
  - circular dichroism 127; 235
  - classification
    - vessel disease 60
  - clusterin 208; 329; 342; 343 *See also*
    - apolipoprotein J
  - coagulopathy 6; 12
  - collagen 24; 38; 169; 191; 192; 193; 195; 203; 210; 217; 227; 228
  - complement factors 202; 207; 208; 211; 213; 215; 229
  - computed tomography (CT) 23; 24; 37; 292
  - Congo red 11; 25; 26; 123; 124; 141; 145; 158; 183; 208; 215; 227; 234; 270; 271; 273; 275; 278; 300 *See also*
    - birefringence
  - congophilic 11; 104; 123; 124; 141; 153; 158; 173; 217; 218; 234; 236; 243; 265; 278; 313; 322; 333
  - cortical vessels
    - A $\beta$  159
  - Creutzfeldt-Jakob disease 96; 196; 204; 239; 247
  - criteria
    - Boston 10
    - Braak & Braak 140
    - CERAD 140; 281
    - NIA/Reagan Institute 140
    - NINCDS/ADRDA 21; 29
  - CSF *See* cerebrospinal fluid
  - CT *See* computed tomography
  - C-terminal antibodies
    - A $\beta$  168; 181; 317
  - cyclooxygenases 288; 290
  - cynomolgus monkeys 27; 38; 311; 317; 321
  - cystatin C 5; 12; 15; 18; 82; 91; 100; 104; 114; 121; 123; 124; 125; 126; 127; 128; 129; 130; 131; 132; 133; 134; 150; 154; 209; 234; 238; 258; 263; 313; 315; 317; 324
  - amyloid fibril formation 129
  - amyloid formation 127; 128
  - dimers 127; 128
  - gene 126
  - intracellular accumulation 127
  - mutation 104
- degeneration
    - endothelium 157; 195; 267
    - microvascular 18; 64; 71; 123; 129; 149; 155; 189; 190; 223; 228; 232; 266; 277
    - pericytes 73; 267; 268; 271; 275
    - smooth muscle cells 73; 157; 195; 227; 256; 258; 266; 267; 268; 275; 286
  - diabetes mellitus 45; 65
  - diffusion coefficients 28
  - double-barrel 86
  - Down's syndrome 85; 92; 93; 100; 101; 109; 152; 158; 173; 183; 187; 191; 195; 196; 217; 218; 267; 302; 308; 329; 339
  - Dutch mutation *See* amyloid  $\beta$  precursor protein gene
  - dyschoric angiopathy 139
  - dystrophic neurites 240; 273; 300; 327
- ECM *See* extracellular matrix
  - EDRF *See* endothelium-derived relaxing factor
  - eicosanoids 288
  - ELISA 181; 304
  - endothelial cells 23; 24; 25; 30; 33; 51; 58; 65; 78; 157; 161; 209; 213; 219; 231; 286; 299; 325; 328; 341; 343
  - endothelin-1 281; 284
  - endothelium
    - degeneration 195; 267
  - endothelium-derived relaxing factor (EDRF) 65
  - entorhinal cortex 23; 37; 93; 302; 308
  - estrogen 112
  - extracellular matrix (ECM) 63; 159; 161; 169; 170; 210; 213; 215; 218; 219;

- 227; 234; 252; 257; 258; 260; 302;  
304; 306; 309
- familial British dementia (FBD) 237; 238;  
243; 247; 272
- familial cerebral amyloid angiopathy -  
British type *See* familial British  
dementia
- fatty acids  
CAA 162; 163
- fatty streak 61; 74
- FBD *See* familial British dementia
- fibrillogenesis 98; 230; 235; 340; 345
- fibrinoid deposits 71
- fibrinoid necrosis 64; 65; 72; 81; 87; 91;  
143; 144; 147; 148; 149; 228; 265
- fibromuscular dysplasia 60; 63
- fibromuscular hyperplasia 64
- fibronectin 210; 227
- fibrosis 123; 210; 228; 267
- fibrous plaques 61
- fish consumption 46
- Flemish mutation *See* amyloid  $\beta$   
precursor protein gene
- Florida mutation *See* amyloid  $\beta$  precursor  
protein gene
- folate 49; 56; 57
- foreign body giant cells 147; 151
- formic acid 37; 159; 161; 162; 165; 168;  
172; 179; 180; 181
- free oxygen radicals 215
- free radical 275; 279; 284; 292
- furin 244
- gamma-glutamyl transferase 192
- gas chromatography-mass spectrometry  
162
- genetic imprinting 112
- Gerstmann-Sträussler-Scheinker disease  
239; 246; 247
- giant cell reaction 5; 8; 17; 63
- giant cells  
foreign body 147
- glucose transporter 191; 193; 200; 201
- glycolipids  
CAA 161
- glycoproteins  
CAA 161
- gp330/megalin 33; 325; 330; 332; 333
- gradient-echo MRI 3; 12; 13; 18
- granular osmiophilic materials 71
- granulomatous angiitis 147; 150
- HCCAA *See* hereditary cerebral  
hemorrhage with amyloidosis-  
Icelandic type
- HCHWA-D *See* hereditary cerebral  
hemorrhage with amyloidosis-Dutch  
type  
 $A\beta_{1-40}$  269  
 $A\beta_{1-42}$  270
- HCHWA-I *See* hereditary cerebral  
hemorrhage with amyloidosis-  
Icelandic type
- head injury 81; 93; 94; 101; 196
- head trauma 10; 81; 90; 91; 147
- hematoma 6; 7; 10; 11; 13; 16; 94; 143;  
144
- hemorrhage  
clinical outcome 7  
hypertensive 4  
intracerebral 197  
intraparenchymal 66  
lobar 3; 4; 6; 9; 11; 18; 91; 224  
non-lobar 6  
parenchymal 144; 147  
posterior fossa 144  
recurrence 7; 9  
risk of 141  
subarachnoid 93; 144
- hemorrhagic strokes 9; 103; 105; 106;  
107; 108; 196
- hemosiderin 142; 143
- heparan sulfate proteoglycans (HSPGs)  
207; 209; 218; 227; 254; 261; 262;  
304; 309; 327
- heparin 15; 99; 230
- hereditary cerebral hemorrhage with  
amyloidosis 93
- hereditary cerebral hemorrhage with  
amyloidosis-Dutch type (HCHWA-D)  
103; 104; 115; 118; 121; 182; 204;  
210; 223; 233; 234; 257; 266; 279;  
316; 323; 327; 339  
 $A\beta$ -associated proteins 210  
CAA 184; 224  
clinical aspects 104  
epidemiology 105  
radiological aspects 105  
senile plaques 228

- tangles 229
- hereditary cerebral hemorrhage with amyloidosis-Icelandic type (HCHWA-I) 104; 122; 237; 265
  - epidemiology 136
- hereditary cerebral hemorrhage with amyloidosis-Italian type 108
- hereditary cystatin C amyloid angiopathy
  - See* hereditary cerebral hemorrhage with amyloidosis-Icelandic type
- hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS) 72; 77
- HERNS *See* hereditary endotheliopathy with retinopathy, nephropathy, and stroke
- high molecular weight-melanoma associated antigen 268
- hill and valley 251
- Hirano bodies 46; 54
- homocysteine 46; 65
- Honolulu-Asia Aging Study 36; 45; 53
- HSPGs *See* heparan sulfate proteoglycans
- hyaline thickening 64
- hyalinization 66; 69; 70; 123; 228; 267
- hyperglycemia 45
- hypertension 4; 14; 17; 44; 53; 55; 57; 64; 65; 66; 70; 72; 81; 87; 90; 91; 104; 145; 146; 149; 189; 190; 191; 194; 198; 199; 200; 203; 204; 281; 292
- hypoperfusion 157; 191; 196; 204; 227; 282
  
- ICAM-1 *See* intercellular adhesion molecule-1
- imaging 10; 18; 21; 22; 23; 26; 27; 29; 32; 34; 35; 36; 39; 69; 71; 76; 77; 103; 106; 195; 198; 200; 201; 206; 292; 314; 315; 322
- immuno-electron microscopy 227
- incidence
  - gender-specific 43
- inflammation 50
- inflammatory infiltrate 148
- inflammatory proteins 50; 51; 186; 191; 193; 207; 208; 212; 215; 227; 229; 281; 288; 290; 328
- inflammatory reaction 151
- injection
  - intrathecal 27
- insulin 21; 33; 34; 35; 40; 41; 45; 53; 54; 78; 330; 343
- intercellular adhesion molecule-1 (ICAM-1) 61; 193; 202; 209; 218; 219; 268
- interleukin-1 211; 219
- interleukin-6 51; 212
- internalization
  - A $\beta$  251; 253; 255; 289; 329
  - ApoE 253; 304
- interstitial fluid 22; 37; 169; 172; 204; 214; 220; 232; 236; 256; 274; 309
- ischemic lesions 105; 138
- ischemic vascular dementia 72
- Italian mutation *See* amyloid  $\beta$  precursor protein gene
  
- Katwijk
  - families 105; 223
- knock-out 73; 93; 335
- Kunitz protease inhibitor 109
  
- lactoferrin 209; 210
- lacunar infarcts 66; 68; 69; 199
- laminin 230
- Leiden mutation 50
- leptomeningeal vessels
  - A $\beta$  158
- leukoaraiosis 69; 76; 200; 203; 205
- leukoencephalopathy 9; 17; 59; 60; 66; 68; 69; 70; 77; 81; 92; 99; 131; 144; 218; 224; 227
  - CAA-related 92
- Lewy bodies 225
- lipohyalinosis 59; 60; 64; 66; 72; 73; 200
- lipoprotein receptors 332; 333; 343 *See also* low density lipoprotein receptor-related protein
- lipoxigenases 288; 291
- lobar hemorrhages 3; 4; 6; 9; 11; 18; 91; 224
- locus ceruleus 171
- London mutation *See* amyloid  $\beta$  precursor protein gene
- low density lipoprotein receptor-related protein (LRP) 95; 253; 301; 343
- LRP *See* low density lipoprotein receptor-related protein
- lysosome-associated membrane protein 253

- macroangiopathy 60  
 $\alpha_2$ -macroglobulin 95; 209; 210; 211; 301; 326; 333  
magnetic resonance imaging 12; 23; 69; 71; 106; 111; 198; 200 *See also*  
nuclear magnetic resonance  
MALDI-TOF 163  
mental deterioration 68  
microaneurysm 66; 73; 76; 78; 87; 137; 141; 143; 146; 147; 149; 150; 153; 228; 265; 267  
Charcot-Boucharard 141  
microangiopathy 72; 73  
CAA-associated 148; 149  
microatheroma 65; 66  
microglia  
activated 57; 91; 217; 227; 288; 305; 328  
perivascular activated 91  
scavenger receptors 305  
microglial cells 210  
microinfarcts 87; 144; 149; 191; 198; 199  
microvascular degeneration 18; 64; 71; 123; 129; 149; 155; 189; 190; 223; 228; 232; 266; 277  
mongrel dogs  
CAA 314  
monoamine oxidase 192  
monosaccharides  
CAA 163  
MRI *see* magnetic resonance imaging  
mutant APP *See* amyloid  $\beta$  precursor protein gene  
  
NAC *See* non-A $\beta$  component of AD amyloid  
neurofibrillary tangles 44; 46; 49; 53; 81; 84; 96; 97; 111; 123; 137; 138; 188; 189; 190; 195; 200; 218; 219; 229; 240; 242; 244; 246; 266; 273; 321; 326  
neuropil threads 229; 240; 266; 273  
NIA/Reagan Institute 140  
NINCDS-ADRDA criteria 21; 29  
nitric oxide synthase (NOS) 65; 286; 287  
NMR *See* nuclear magnetic resonance  
non steroid anti-inflammatory drugs (NSAIDs) 50  
non-A $\beta$  component of AD amyloid (NAC) 209  
nonhuman primates 313; 314; 316; 317; 323; 343  
CAA 314  
NOS *See* nitric oxide synthase  
Notch3 71, 73  
NSAIDs *See* non steroid anti-inflammatory drugs  
N-terminal antibodies  
A $\beta$  164; 168  
nuclear magnetic resonance (NMR) 127; 163 *See also* magnetic resonance imaging  
nucleus basalis magnocellularis 171  
nucleus basalis of Meynert 171  
  
onion-skin type 64  
oxidative stress 193; 196; 279; 328; 342  
  
paired helical filaments 162; 174; 239  
Pantelakis  
l'angiopathie congophile de 226  
Paquid study 51  
PDGF *See* platelet-derived growth factor  
pentraxins 194  
pericytes 59; 73; 161; 179; 209; 213; 214; 215; 216; 220; 231; 251; 255; 256; 259; 265; 266; 267; 268; 269; 270; 271; 272; 274; 275; 277; 278; 305  
amyloid  $\beta$  precursor protein 272  
CAA 255; 274  
culture 267; 272  
degeneration 73; 267; 268; 271; 275  
*See also* microvascular degeneration  
isolation 268  
scavenger receptors 305  
viability 268, 269; 270; 272; 273  
perlecan 176; 263; 304; 309 *See also*  
heparan sulfate proteoglycans  
permability-surface area product 34; 330  
PET *See* positron emission tomography  
phospholipase A<sub>2</sub>  
platelet-derived growth factor (PDGF)  
61; 73; 254  
 $\beta$ -pleated sheet 158; 230; 244; 273; 274  
polar bears 184  
positron emission tomography (PET) 23; 24; 26; 31; 38; 39; 191; 282; 292  
post-translational modifications  
A $\beta$  164



- presenilin-1 (PS-1) 110; 116; 117; 118;  
 184; 185; 188; 308  
 presenilin-2 (PS-2) 103; 110  
 prion protein cerebral amyloid angiopathy  
 (PrP-CAA) 238  
 probable AD 11; 21; 23; 24; 29  
 protease nexin-2 109  
 PrP gene  
 mutations 239  
 PrP-CAA *See* prion protein cerebral  
 amyloid angiopathy  
 PS-1 *See* presenilin-1  
 PS-2 *See* presenilin-2
- radiopharmaceutical 34; 35; 40  
 radiotracers 26  
 RAGE *See* receptor for advanced  
 glycation end products  
 RAP *See* receptor associated protein  
 reactive astrocytes 227  
 reactive oxygen species 275  
 receptor associated protein (RAP) 253;  
 332  
 receptor for advanced glycation end  
 products (RAGE) 328; 329  
 rhesus monkeys 26; 27; 34; 35; 313; 317;  
 319; 324  
 Rotterdam Study 45; 46; 47; 50; 51; 52;  
 54; 55; 56; 57; 58; 205
- scanning electron microscopy 267  
 scavenger receptors 254; 261; 305; 328;  
 341  
 microglia 305  
 pericytes 305  
 Scheveningen  
 families 105; 223  
 $\alpha$ -secretase 109; 110; 112; 113  
 $\beta$ -secretase 23; 109; 113  
 $\gamma$ -secretase 23; 109; 110; 112; 113  
 senile plaques  
 A $\beta$ -associated proteins 210  
 HCHWA-D 228  
 serum amyloid P *See* amyloid P  
 component  
 Seven Countries Study 46  
 single photon emission computed  
 tomography (SPECT) 23; 26; 29; 30;  
 282  
 SMCs *See* smooth muscle cells
- smoking 48  
 smooth muscle  $\alpha$ -actin 252; 268  
 smooth muscle cells (SMCs) 59; 61; 63;  
 64; 65; 71; 77; 78; 86; 98; 123; 141;  
 142; 146; 174; 175; 179; 185; 186;  
 190; 193; 195; 203; 209; 210; 213;  
 214; 215; 216; 227; 231; 251; 261;  
 262; 263; 265; 266; 267; 268; 269;  
 270; 271; 272; 274; 276; 277; 278;  
 279; 286; 291; 292; 293; 301; 308;  
 310; 314; 322; 328; 341; 346  
 A $\beta$  binding 252  
 A $\beta$  internalization 289  
 A $\beta$  precursor protein 272  
 A $\beta$  processing  
 A $\beta$  production  
 CAA 255; 274  
 canine 253  
 degeneration 73; 157; 195; 227; 256;  
 258; 267; 268; 271; 275; 286; 328  
 differentiation 252; 260  
 viability 267; 268; 270; 272  
 SPECT *See* single photon emission  
 computed tomography  
 squirrel monkeys 26; 27; 28; 30; 32; 258;  
 263; 296; 313; 316; 317; 319; 320;  
 321; 323; 324; 329; 337  
 stroke 59; 66; 69; 71; 93; 104; 105; 108;  
 122; 138; 149; 197; 199; 223; 231  
 hemorrhagic 4; 8  
 studies and trials  
 Cardiovascular Health Study 47; 69;  
 77  
 Honolulu-Asia Aging Study 36; 45; 53  
 Paquid Study 51  
 Rotterdam Study 45; 46; 47; 50; 51;  
 52; 54; 55; 56; 57; 58; 205  
 Seven Countries Study 46  
 Syst EUR Trial 44  
 TIMI II trial 6  
 superoxide dismutase 286; 305  
 Swedish mutation *See* amyloid  $\beta$   
 precursor protein gene  
 Syst-EUR Trial 44
- tau 22; 37; 176; 228; 229; 231; 240; 241;  
 244; 246; 324; 333; 337; 345  
 TGF $\beta$ 1 *See* transforming growth factor  
 $\beta$ 1  
 thioflavin S 242; 298; 300

- thrombosis 50  
 TIAs *See* transient ischemic attacks  
 tight junctions 24; 192; 195; 216  
 TIMI II trial 6  
 tissue bath system 283; 290  
 $\gamma$ -trace 31; 209 *See also* cystatin C  
 transcytosis 30; 33; 35; 40; 41; 175; 325; 328; 329; 330; 337; 342; 343  
 transferrin receptor 33; 34; 41; 330  
 transforming growth factor  $\beta$ 1 (TGF $\beta$ 1)  
   126; 254; 300; 304  
   transgenic mice 300  
 transgenic mice 38; 73; 86; 255; 259; 261; 282; 295; 296; 297; 300; 306; 307; 308; 309; 310; 313; 314; 318; 322; 346  
   APP 296; 302; 303  
   mutant APP 86  
   PDAPP and TGF $\beta$ 1 300  
   TGF $\beta$ 1 300  
 transgenic mouse models 282; 283; 296; 314; 335 *See also* animal models  
   APP23 297; 300  
   APP670/671NL 110; 111; 184; 297  
   APP717F 110; 111; 184; 296; 297; 302  
   APPsw line Tg2576 297; 298; 299; 301; 335  
   PDAPP line 109 297  
 transient ischemic attacks (TIAs) 8; 17; 62; 99; 144  
 transthyretin 82; 121; 130; 238; 244; 258; 310; 326; 328; 329  
   Hungarian kindred 238  
   Ohio kindred 238  
 trials *See* studies and trials  
 tunica media 169; 314; 316
- vascular amyloid *See also* cerebral amyloid angiopathy  
   APP23 transgenic mice 297; 300  
   cynomolgus monkeys 317  
   fatty acids 162; 163  
   glycolipids 161  
   glycoproteins 161  
   monosaccharides 163  
   neuronal source 302  
   neurons 302  
   nonhuman primates 316; 319  
   rhesus monkeys 317  
   source 301  
   Tg2576 transgenic mice 297; 298; 299; 301  
 vascular dementia 44; 45; 48; 50; 53; 54; 72; 76; 77; 106; 194; 198; 199; 200; 201; 203; 205; 206  
 vasculitis 8; 12; 60; 146; 149; 150; 170  
 vasculopathy 7; 10; 14; 59; 60; 63; 86; 99; 140; 146; 200; 204; 220  
   CAA-associated 86  
 vasoconstriction 281; 282; 284; 286; 287; 288  
   endothelin-1 284  
 vasorelaxation 282  
 very low density lipoprotein (VLDL)  
   receptor 333; 343  
 vessel diseases  
   classification of 60  
 vessels  
   hyalinization 123  
 vessel-within-a-vessel 86; 143; 147  
 viability  
   pericytes 268, 269; 270; 272; 273  
   smooth muscle cells 267; 268; 270; 272  
 Virchow-Robin spaces 69  
 vitamin B12 49; 56; 57  
 VLDL receptor *See* very low density lipoprotein receptor
- warfarin 6; 10; 15; 16; 99  
 white matter hyperintensities 76; 103; 106; 107; 108; 115; 232  
 Worster-Drought kindred 243
- <sup>111</sup>In 34; 43  
<sup>123</sup>I 35; 41; 44  
<sup>124</sup>I 35  
<sup>125</sup>I 34; 36; 38; 39; 43; 44; 197; 359; 367; 375; 380  
<sup>68</sup>Ga 26; 42  
<sup>99m</sup>Tc 31